239 related articles for article (PubMed ID: 21672888)
21. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
Dawson LA
Expert Opin Drug Discov; 2013 Dec; 8(12):1529-39. PubMed ID: 24195711
[TBL] [Abstract][Full Text] [Related]
22. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
Khan A; Sambunaris A; Edwards J; Ruth A; Robinson DS
Int Clin Psychopharmacol; 2014 Mar; 29(2):86-92. PubMed ID: 24247740
[TBL] [Abstract][Full Text] [Related]
23. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
[TBL] [Abstract][Full Text] [Related]
25. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study.
Edwards J; Sperry V; Adams MH; Gallipoli S; Thorn MD; Longstreth J; Boinpally R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):456-65. PubMed ID: 23611569
[TBL] [Abstract][Full Text] [Related]
26. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
27. Vilazodone: another novel atypical antidepressant drug.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Mar; 49(3):19-22. PubMed ID: 21323263
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.
Thase ME; Chen D; Edwards J; Ruth A
Int Clin Psychopharmacol; 2014 Nov; 29(6):351-6. PubMed ID: 24978955
[TBL] [Abstract][Full Text] [Related]
29. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
30. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.
de Paulis T
IDrugs; 2007 Mar; 10(3):193-201. PubMed ID: 17351874
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
32. Vilazodone's comparative merits yet to be demonstrated.
Dopheide JA
Am J Health Syst Pharm; 2012 Sep; 69(18):1549. PubMed ID: 22935936
[No Abstract] [Full Text] [Related]
33. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
Stahl SM
CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
[TBL] [Abstract][Full Text] [Related]
34. Evidence for the use of vilazodone in the treatment of major depressive disorder.
Reinhold JA; Mandos LA; Lohoff FW; Rickels K
Expert Opin Pharmacother; 2012 Oct; 13(15):2215-24. PubMed ID: 22970859
[TBL] [Abstract][Full Text] [Related]
35. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
[TBL] [Abstract][Full Text] [Related]
36. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Mandrioli R; Mercolini L; Saracino MA; Raggi MA
Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
[TBL] [Abstract][Full Text] [Related]
37. Vilazodone: a review in major depressive disorder in adults.
McCormack PL
Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
[TBL] [Abstract][Full Text] [Related]
38. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
40. Vilazodone (viibryd) for the treatment of depression.
Gazewood JD; Slayton P; Degeorge K
Am Fam Physician; 2013 Aug; 88(4):263-4. PubMed ID: 23944730
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
